Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.

Area of Science:

• Hematology
• Molecular Biology
• Epigenetics
• Cancer Therapy

Background:

• All-trans retinoic acid (ATRA) is effective for acute promyelocytic leukemia (APL).
• Retinoic acid (RA)-based therapies are being explored for other acute myeloid leukemia (AML) subtypes.
• Current clinical trials show limited success for ATRA in non-APL AML, necessitating biomarker discovery.

Purpose of the Study:

• To explore the potential of retinoic acid (RA)-based therapies for non-acute promyelocytic leukemia (non-APL) subtypes of acute myeloid leukemia (AML).
• To identify biomarkers predicting response to ATRA in AML patients.
• To investigate epigenetic and transcriptional states influencing ATRA susceptibility and explore novel combination therapies.

Main Methods:

• Review of current knowledge on epigenetic aspects of RA-induced differentiation in APL and non-APL AML.
• Hypothesizing that epigenetic reprogramming via enzyme inhibitors or microRNA modulation can sensitize AML cells to RA.
• Focus on understanding the role of epigenetic states in leukemic stem cell (LSC) survival and differentiation.

Main Results:

• ATRA can induce differentiation and/or apoptosis in a subset of AML patients with specific mutations (NPM1, FLT3-ITD, IDH1) or EVI-1 overexpression.
• Not all patients within these subgroups respond to ATRA, highlighting the need for additional biomarkers.
• Preliminary evidence suggests epigenetic and transcriptional states dictate ATRA susceptibility.

Conclusions:

• Identifying predictive biomarkers is crucial for selecting AML patients who will benefit from ATRA-based therapies.
• Epigenetic reprogramming strategies may overcome resistance and sensitize non-APL AML cells to RA-based treatments.
• Targeting leukemic stem cells (LSCs) through differentiation therapies is essential for improving AML patient prognosis.